Navigation Links
Delcath To Present At JMP Securities Healthcare Conference On July 12
Date:7/9/2012

NEW YORK, July 9, 2012 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH) announced today that executive management will present an overview of the Company's business strategy and recent corporate developments at the JMP Securities Healthcare Conference in New York on Thursday, July 12, 2012 at 1:30 P.M. ET.

A live webcast and subsequent archived replay of the presentation will be available at http://www.delcath.com/investors/events/.  The presentation archived replay will be available approximately one hour after conclusion of the live event for a period of 90 days.

About Delcath Systems

Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology. Delcath's proprietary system for chemosaturation is designed to administer high dose chemotherapy and other therapeutic agents to diseased organs or regions of the body, while controlling the systemic exposure of those agents. The Company's initial focus is on the treatment of primary and metastatic liver cancers. In 2010, Delcath announced that its randomized Phase III clinical trial for patients with metastatic melanoma in the liver had successfully achieved the study's primary endpoint of extended hepatic progression-free survival. The Company also completed a multi-arm Phase II trial to treat other liver cancers. The Company obtained authorization to affix a CE Mark for the Delcath Hepatic CHEMOSAT® delivery system in April 2011 and for the second generation hemofiltration cartridge for CHEMOSAT in April 2012. The right to affix the CE mark allows the Company to market and sell the CHEMOSAT system in Europe. The Company has not yet received FDA approval for commercial sale of its system in the United States. The Company continues with the preparation of its NDA submission and intends to seek FDA approval for commercial sale of its chemosaturation system with melphalan. For more information, please visit the Company's website at www.delcath.com.

Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to: future use of the second generation hemofiltration cartridge in the Expanded Access Program and clinical trials in the United States, the benefits of the Generation 2 CHEMOSAT system and market acceptance of the same, patient outcomes using the Generation 2 system, the timing of the supply and distribution of the CHEMOSAT system to early launch centers in Europe, the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, , the timing and use, if any, of the line of credit from SVB, and our ability to access this facility, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

Contact Information: Investor Contact:                                             Media Contact: Doug Sherk/Gregory Gin                                  Janine McCargo EVC Group                                                     EVC Group 415-568-4887/646-445-4801                             646-688-0425


'/>"/>
SOURCE Delcath Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Delcath Systems, Inc. Secures $20 Million Credit Facility
2. Delcath Highlights First Quarter 2012 And Recent Accomplishments
3. Delcath to Webcast Managements Presentation at Annual Meeting of Stockholders
4. Delcath Prices $20 Million Public Offering of Common Stock and Warrants
5. Delcath To Offer Second Generation Hemofiltration Cartridge In U.S. Expanded Access Program
6. Delcath Announced Changes To Board Of Directors
7. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
8. Latest Findings in Breastfeeding Science Presented at Medelas 7th International Breastfeeding and Lactation Symposium
9. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
10. Enox Biopharma, Inc. To Present Today At IN3 Medical Device 360 Conference In London
11. Foundation for Managed Care Pharmacy (FMCP) Presents Awards for 2012 National P&T Competition and Best Posters
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2020)... ... January 10, 2020 , ... Cytonus ... been selected to present at next week’s Biotech Showcase. Cytonus is a ... its proprietary Cargocyte™ next generation Adoptive Cellular Therapy (ACT) technologies which have ...
(Date:1/12/2020)... (PRWEB) , ... January 11, 2020 , ... New ... than a regular vacation and information on how to book an affordable option. , ... get away from the frenetic pace of everyday life, sight see and a try ...
(Date:1/10/2020)... ... January 10, 2020 , ... Braid.Health — ... and the healthcare industry — today announced the appointment of Connie Phelps as ... experience, working with health systems in sales and marketing leadership roles. Phelps was ...
Breaking Medicine Technology:
(Date:1/23/2020)... ... 23, 2020 , ... The American Heart Association (AHA), the leading voluntary health ... Ventura County Go Red for Women Luncheon will take place Friday, February 21, ... 500 residents are anticipated to attend the premier event designed to raise awareness and ...
(Date:1/23/2020)... , ... January 23, 2020 , ... ... RespirCare, LLC, a first-of-its-kind, full-service pulmonology clinic based in Tulsa, to provide patients ... agreement, MCNDOH patients will also have access to HGE Health’s digital symptom management ...
(Date:1/23/2020)... (PRWEB) , ... January 23, 2020 , ... Merger and ... in the fourth quarter of 2019, according to data from HealthCareMandA.com. The total is ... fourth quarter in 2018, when 65 deals were announced. , One deal disclosed a ...
(Date:1/23/2020)... (PRWEB) , ... January 23, 2020 , ... ... of providing programs and services that improve workforce resilience, is presenting at the ... serves as an advocate and resource for organizations that devote themselves to society’s ...
(Date:1/23/2020)... , ... January 23, 2020 ... ... engagement SaaS vendor announced their partner agreement with Healthpac, a trusted medical ... billing offices and medical offices an expanded offering. Healthpac’s customers can now ...
Breaking Medicine News(10 mins):